Joseph Weinstein, MD
Interventional Cardiology · Memphis, TNNPI 1922003037
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $163,575 of the $218,322 with a category attached, or 74.9%. Johnson & Johnson accounts for 91.5% of it on its own, with 41 other manufacturers making up the rest. Reporting peaked in 2019 at $117,583 and has fallen 99.0% since, to $1,165 in 2025. Among interventional cardiology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 691 payments — averaging $315.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$200K
- Medtronic$4K
- Biotronik Inc.$2K
- Esperion Therapeutics, Inc.$2K
- Abiomed$1K
- Abbott$1K
- plus $9K from 36 others
Across 12 payments — averaging $43,973 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$484K
- AstraZeneca$44K
What the payments were for
- Consulting fees$4250%
- Speaking & faculty fees$163,57575%
- Travel & lodging$34,31316%
- Food & beverage$19,8369%
- Education$1730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$196,664
- Resolute$1,790
- NEXLIZET$1,620
- NEXLETOL$1,620
- Impella$685
- Indigo System$384
- AVVIGO Guidance System$291
- LifeVest$242
- TELEPATCH CARDIAC MONITOR$178
- QUADRA ASSURA$172
- ELLIPSYS VASCULAR ACCESS SYSTEM$155
- ENSITE PRECISION$151
- Hillrom - Cardiac Ambulatory Monitor$147
- OPTIMIZER$145
- Allure CRT Pacemaker$137
- Ellipsys$137
- Aquadex$131
- HawkOne$128
- Adempas$125
- Carnation Ambulatory Monitor$125
How this compares
$218,322 in reported general payments places this provider in the 95th percentile of 207 interventional cardiology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 563 | $473,226 |
| Repatha SureclickEvolocumab | 272 | $190,213 |
| EntrestoSacubitril/Valsartan | 132 | $136,596 |
| EliquisApixaban | 123 | $109,089 |
| JardianceEmpagliflozin | 65 | $58,483 |
| FarxigaDapagliflozin Propanediol | 50 | $42,242 |
| OzempicSemaglutide | 41 | $40,893 |
| Praluent PenAlirocumab | 68 | $40,093 |
| MultaqDronedarone Hcl | 33 | $37,158 |
| BrilintaTicagrelor | 59 | $36,112 |
| MounjaroTirzepatide | 19 | $19,385 |
| Nebivolol Hcl | 375 | $17,869 |
| Ranolazine ErRanolazine | 156 | $17,646 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 23 | $12,670 |
| Rosuvastatin Calcium | 673 | $9,759 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $199,792 | $473,226563 claims |
| NovartisEntresto | $783 | $136,596132 claims |
| PfizerEliquis | $212 | $109,089123 claims |
| AstraZenecaFarxiga, Brilinta | $655 | $78,354109 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $427 | $71,15288 claims |
| Novo NordiskOzempic | $38 | $40,89341 claims |
| Sanofi-aventis U.S. LLCMultaq | $280 | $37,15833 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $38 | $6,96518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 207 interventional cardiology providers in Tennessee.
Other interventional cardiology in Memphis
- Dwight DishmonMemphis$133K
- Claro DiazMemphis$109K
- Benjamin WallerMemphis$52K
- Mohamed MorsyMemphis$20K
- Stevan HimmelsteinMemphis$15K
- Jimmy KerriganNashville$644K
- Kashish GoelNashville$558K
- Brian JeffersonNashville$547K
- Malcolm FosterKnoxville$413K
- Mehul PatelGermantown$382K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.